Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Regulatory policy for the development of targeted therapies for low-frequency molecular subtypes of disease

Numerous challenges arise when developing targeted therapies for diseases comprising low-frequency molecular subtypes. In this article, we describe a pragmatic, science-based regulatory policy for the development and approval of targeted therapies in such cases.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Pacanowski, M. A., Leptak, C. & Zineh, I. Next-generation medicines: past regulatory experience and considerations for the future. Clin. Pharmacol. Ther. 95, 247–249 (2014).

    Article  CAS  Google Scholar 

  2. Biankin, A. V., Piantadosi, S. & Hollingsworth, S. J. Patient-centric trials for therapeutic development in precision oncology. Nature 526, 361–370 (2015).

    Article  CAS  Google Scholar 

  3. Durmowicz, A. G. et al. The FDA's experience with ivacaftor in cystic fibrosis: establishing efficacy using in vitro data in lieu of a clinical trial. Ann. Am. Thorac. Soc. https://dx.doi.org/10.1513/AnnalsATS.201708-668PS (2017).

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Issam Zineh.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Related links

Related links

FURTHER INFORMATION

US Food and Drug Administration. Paving the way for personalized medicine

US Food and Drug Administration. Guidances (Drugs)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schuck, R., Pacanowski, M., Woodcock, J. et al. Regulatory policy for the development of targeted therapies for low-frequency molecular subtypes of disease. Nat Rev Drug Discov 17, 79–80 (2018). https://doi.org/10.1038/nrd.2017.231

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2017.231

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research